Abstracts Submission Deadline Extended February 27th
Abstract Notifications to Authors End of March 2017
The Scientific Committee invites authors to submit their abstracts for consideration and inclusion in the program. All accepted abstracts accepted as Oral or Poster presentations require that at least one author attend the congress to present the work and answer questions. Only abstracts of registered participants will be scheduled in the Scientific Program.
Abstracts submitted to EPA-UNEPSA meetings should focus on scientific findings and must not be abused to promote products or companies. Any financial support by commercial companies and any ties to commercial companies such as employment and honoraria must be transparently disclosed. The use of brand names of commercial products should be avoided, unless the disclosure of brand names is necessary for the understanding of the abstract in which case the brand name should not be used more than once.
Oral and poster presentations should focus on the presentation and discussion of scientific data and not in any way be abused for marketing or advertising purposes. Any financial support by commercial companies any ties to commercial companies such as employment and honoraria must be transparently disclosed. The name of companies linked to the research should be disclosed but no company logos should be used in scientific presentations in order to avoid even the suspicion of undue promotional activities. The use of brand names of commercial products should be avoided, unless the disclosure of brand names is necessary for the understanding of the presentation in which case the brand name should not be used more than once.
All abstracts must be submitted and presented in clear English with accurate grammar and spelling suitable for publication.
Only the abstracts of registered presenting authors will be included in the final program.
Registration fees must be received by the Secretariat by Tuesday, April 11, 2017.
The Scientific Committee will determine whether abstracts will be accepted as oral or poster presentations, with consideration to be given to the author's preference.
Abstracts will be reviewed and assigned to appropriate sessions. The author is expected to attend the congress and present the poster.
All submitted abstracts must contain novel data.
If an abstract was previously submitted to a different congress, but was not presented, it can be submitted to this congress as well. If it was previously presented, it cannot be submitted.
Authors of all abstracts are required to grant an exclusive licence on a worldwide basis to the BMJ and/or co-owners or contracting owning societies (where published by the BMJ on their behalf) in accordance with our standard licence.
Be aware that by submitting your work for publication authors are agreeing to the terms and conditions of BMJ’s standard licence to publish for abstracts, which can be found at http://journals.bmj.com/site/authors/Abstract_licence_Oct_2014.pdf.
As this is an exclusive licence, authors must sign agreement to this licence before publication.
The abstract may be submitted in English on the official workshop website system.
The abstract may be submitted in English on the official congress website system latest by February 27th.
All abstracts will be reproduced in the Abstracts e-book, exactly in the form you submitted. All authors are kindly requested to follow below guidelines while submitting your abstracts. Abstracts will not be edited and authors will not see proofs. Obvious mistakes will be corrected and the abstracts will be amended to house style as appropriate.
Your abstract will be reviewed by the Scientific Committee.
Acknowledgement of acceptance of your abstract will be received via e-mail and on submitter profile page by the end of March, 2017.
Any financial support by commercial companies and any other ties to commercial companies such as employment and honoraria must be transparently disclosed.
The use of brand names of commercial products should be avoided, unless the disclosure of brand names is necessary for the understanding of the abstract or presentation in which case the brand name should not be used more than once.
The name of companies linked to the research should be disclosed but no company logos should be used in scientific presentations in order to avoid even the suspicion of undue promotional activities.
All abstracts accepted for presentation (oral or poster) will be published in digital format within the official abstract book of the meeting.